Oncology

What Exactly is a GIST? Biology and Misdiagnoses

At a Glance

A Gastrointestinal Stromal Tumor (GIST) is a rare cancer starting in the digestive tract's pacemaker cells, usually driven by KIT or PDGFRA mutations. Unlike common stomach cancers, GISTs require specific pathology stains like CD117 and DOG1 for accurate diagnosis and treatment.

To understand what a Gastrointestinal Stromal Tumor (GIST) is, it helps to look at the “wiring” of your digestive system. Unlike common cancers that start in the lining of the stomach or colon, GIST starts in the walls of the gastrointestinal tract, specifically in the cells that control movement.

The “Pacemaker Cells” of the Gut

Deep within the walls of your stomach and intestines are specialized cells called interstitial cells of Cajal (ICCs) ^[1]. These cells are often described as the “pacemakers” of the gut ^[2]. Just as a pacemaker in the heart tells the heart muscle when to beat, these cells send out electrical signals that tell the muscles in your digestive tract when to contract to move food along ^[3]. A GIST is essentially a tumor that grows from these pacemaker cells ^[4].

The “Stuck Gas Pedal” Analogy

In healthy pacemaker cells, growth is strictly controlled by “switches” called receptors. The most important switches in these cells are proteins called KIT and PDGFRA ^[5].

Normally, these switches only turn “on” when the body sends a specific signal that it needs more cells. However, in about 85% to 90% of GIST cases, a mutation (a permanent error in the cell’s DNA) causes these switches to break ^[6]. This break acts like a stuck gas pedal—the signal to grow and divide is constantly turned “on,” even when the body isn’t sending any signal at all ^[7]. Because the pedal is stuck, the cells multiply uncontrollably, eventually forming a tumor ^[7]^[8].

“Wild-Type” GIST

While the vast majority of GISTs are driven by KIT or PDGFRA mutations, about 10% to 15% of cases do not have these specific mutations. These are referred to as Wild-Type or SDH-deficient GISTs ^[9]. This distinction is incredibly important because standard targeted therapies like imatinib often do not work for Wild-Type GISTs ^[10]. If you have a Wild-Type GIST, your treatment will require highly specialized approaches and possibly different medications or clinical trials ^[11].

Why GIST is Not “Typical” Stomach Cancer

Most people think of stomach or colon cancer as adenocarcinoma, which starts in the epithelial cells (the inner lining) of the organ ^[12]. GIST is a sarcoma, meaning it is a mesenchymal tumor that starts in the structural or functional tissues deeper in the wall ^[13]. This distinction is vital because:

Standard chemotherapy used for adenocarcinoma usually does not work for GIST ^[14].
GIST requires targeted therapies that specifically “unstick” that broken gas pedal ^[7].

The Importance of “Staining” (IHC)

Because GIST grows under the surface, it can look identical to other types of tumors under a microscope. To tell them apart, pathologists use a process called immunohistochemistry (IHC), which is like using a molecular highlighter to find specific proteins ^[12].

The most important “highlighters” for GIST are:

CD117 (KIT): This is the primary marker. About 95% of GISTs will “stain” positive for this protein ^[13].
DOG1: Standing for “Discovered On GIST 1,” this is a highly sensitive marker used if the CD117 test is unclear or negative ^[15]^[16].

Common “Mimickers” and Misdiagnoses

Before modern staining techniques were available, GISTs were often misdiagnosed as other types of tumors. Even today, doctors must carefully rule out “mimickers” using specific stains:

Tumor Type	What it is	How doctors tell it apart
Leiomyoma	A benign tumor of the smooth muscle.	Stains positive for Desmin and SMA; usually negative for CD117 ^[17].
Schwannoma	A tumor that grows from nerve sheath cells.	Stains positive for S100; negative for CD117 and DOG1 ^[17].
Adenocarcinoma	The “common” GI cancer of the lining.	Stains positive for Cytokeratin; GIST is usually negative ^[12].

You do not need to memorize these names. Instead, use this knowledge to ensure your doctor has ordered the correct IHC stains, or to advocate for a second pathology opinion to guarantee an accurate diagnosis before starting treatment ^[18]^[19].

Common questions in this guide

How is a GIST different from common stomach or colon cancer?

Most common stomach cancers are adenocarcinomas that start in the inner lining of the organ. A GIST is a sarcoma that starts deeper in the wall of the gastrointestinal tract, requiring different treatments like targeted therapies instead of standard chemotherapy.

What does it mean if my GIST has a KIT or PDGFRA mutation?

These mutations act like a stuck gas pedal in the cells, causing them to constantly grow and divide into a tumor. Knowing your specific mutation helps doctors choose the right targeted therapy to block this growth signal.

What do the CD117 and DOG1 tests mean on my pathology report?

CD117 and DOG1 are specific protein markers that pathologists look for using special stains. Testing positive for these markers helps confirm a GIST diagnosis and rules out other similar-looking tumors.

What is a Wild-Type GIST?

A Wild-Type GIST is a tumor that does not have the common KIT or PDGFRA mutations. Because standard targeted therapies may not work as well, these tumors require specialized treatment approaches or clinical trials.

Could my GIST be misdiagnosed as something else?

Yes, because GISTs grow under the surface of the digestive tract, they can look like other tumors such as leiomyomas or schwannomas under a microscope. Doctors must use specific pathology stains to correctly identify the tumor type and avoid a misdiagnosis.

Curated prompts to bring to your next appointment.

1.Was my tumor tested for both CD117 and DOG1 markers?
2.How does my GIST's specific mutation (like KIT or PDGFRA) affect the 'stuck gas pedal' mechanism?
3.What specific immunohistochemistry (IHC) tests were used to rule out other tumors like leiomyoma or schwannoma?
4.Since GIST is different from common stomach or colon cancers, how does that change the type of chemotherapy or surgery you are recommending?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (19)

1
Gastrointestinal Stromal Tumors of Small Intestine.
Huda T, Singh MP
Surgery journal (New York, N.Y.) 2019; (5(3)):e92-e95 doi:10.1055/s-0039-1694704.
PMID: 31475241
2
Regulation of Gastrointestinal Smooth Muscle Function by Interstitial Cells.
Sanders KM, Kito Y, Hwang SJ, Ward SM
Physiology (Bethesda, Md.) 2016; (31(5)):316-26 doi:10.1152/physiol.00006.2016.
PMID: 27488743
3
Shifting into high gear: how interstitial cells of Cajal change the motility pattern of the developing intestine.
Chevalier NR, Ammouche Y, Gomis A, et al.
American journal of physiology. Gastrointestinal and liver physiology 2020; (319(4)):G519-G528 doi:10.1152/ajpgi.00112.2020.
PMID: 32877218
4
Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib-new ammunition in battling exon 17 mutations.
Eckardt AJ, Klein O
Translational gastroenterology and hepatology 2018; (3()):12 doi:10.21037/tgh.2018.02.01.
PMID: 29552663
5
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.
Wong NACS, Garcia-Petit C, Dangoor A, Andrew N
Cancer genetics 2022; (268-269()):46-54 doi:10.1016/j.cancergen.2022.09.002.
PMID: 36155382
6
Analysis of mutation of the c-Kit gene and PDGFRA in gastrointestinal stromal tumors.
Xu CW, Lin S, Wang WL, et al.
Experimental and therapeutic medicine 2015; (10(3)):1045-1051 doi:10.3892/etm.2015.2613.
PMID: 26622437
7
Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
Bauer S, George S, von Mehren M, Heinrich MC
Frontiers in oncology 2021; (11()):672500 doi:10.3389/fonc.2021.672500.
PMID: 34322383
8
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
Bauer S, Joensuu H
Drugs 2015; (75(12)):1323-34 doi:10.1007/s40265-015-0440-8.
PMID: 26187774
9
Succinate dehydrogenase deficient GIST: Case series and review of literature from a tertiary care center in India.
Santhosh AP, Rastogi S, Shamim SA, et al.
Indian journal of cancer 2025; (62(3)):408-415 doi:10.4103/ijc.ijc_500_24.
PMID: 41272866
10
Case Report: Dramatic response to entritinib in a patient with gastrointestinal stromal tumor positive for NTRK3 fusion.
Dong G, Han P, Zhang Z, et al.
Frontiers in oncology 2025; (15()):1588950 doi:10.3389/fonc.2025.1588950.
PMID: 40900786
11
Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: a case report.
Gowda S, Sandow L, Heinrich MC
Journal of gastrointestinal oncology 2024; (15(2)):788-793 doi:10.21037/jgo-23-767.
PMID: 38756640
12
Epithelioid Gastrointestinal Stromal Tumor of Duodenum Mimicking Adenocarcinoma: A Case Report.
Tiwari SB, Karki S
JNMA; journal of the Nepal Medical Association 2021; (59(244)):1310-1312 doi:10.31729/jnma.6104.
PMID: 35199796
13
Gastrointestinal Stromal Tumors of the Distal Gastrointestinal Tract.
Kelley KA, Byrne R, Lu KC
Clinics in colon and rectal surgery 2018; (31(5)):295-300 doi:10.1055/s-0038-1642053.
PMID: 30186051
14
Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
Huang WK, Wu CE, Wang SY, et al.
Current treatment options in oncology 2022; (23(9)):1303-1319 doi:10.1007/s11864-022-00996-8.
PMID: 35976553
15
A case of KIT negative extra-gastrointestinal stromal tumor arising in the greater omentum with predominant cystic formation.
Nanjo K, Nishimuta Y, Miyasaka M, et al.
Radiology case reports 2021; (16(8)):2315-2318 doi:10.1016/j.radcr.2021.05.061.
PMID: 34194597
16
Extragastrointestinal stromal tumor of lesser omentum: a challenging radiological and histological diagnosis.
Trombatore C, Palmucci S, Angelico G, et al.
Clinical imaging 2015; (39(6)):1123-7.
PMID: 26271149
17
Gastrointestinal stromal tumor of unusual phenotype after imatinib treatment: A case report and diagnostic utility of ETV1 mRNA in situ hybridization.
Jung M, Park SH, Jeon YK, et al.
Medicine 2017; (96(49)):e9031 doi:10.1097/MD.0000000000009031.
PMID: 29245294
18
Gastric glomus tumor: clinical conundrums and potential mimic of gastrointestinal stromal tumor (GIST).
Duan K, Chetty R
International journal of clinical and experimental pathology 2017; (10(7)):7905-7912.
PMID: 31966640
19
Malignant gastrointestinal neuroectodermal tumor: a case report and review of the literature.
Alyousef MJ, Alratroot JA, ElSharkawy T, et al.
Diagnostic pathology 2017; (12(1)):29 doi:10.1186/s13000-017-0620-9.
PMID: 28320420

This page explains GIST tumor biology and pathology terminology for educational purposes. Your oncologist and pathologist are the best sources for interpreting your specific diagnosis and IHC stains.

Get notified when new evidence is published on Gastrointestinal stromal tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents